Diffuse large B-cell lymphomas with plasmablastic differentiation.
Diffuse large B-cell lymphomas with plasmablastic differentiation.
复制标题
DOI：
10.1007/s11912-005-0062-5
复制
发表时间：
2005-09-01
影响因子：
4.7
通讯作者：
Teruya-Feldstein, Julie
中科院分区：
文献类型：
--
作者：
Teruya-Feldstein, Julie
最近的证据表明，弥漫性大B细胞淋巴瘤（DLBCL）与浆细胞分化代表了一个临床异质性谱，不同的临床病理特征代表不同的实体。具有浆母细胞特征和终末B细胞分化的DLBCL亚型包括口腔粘膜型浆母细胞淋巴瘤（PBL）;具有浆细胞分化的PBL;原发性渗出性淋巴瘤（PEL）; KSHV阳性实体淋巴瘤/腔外PEL/HHV-8相关DLBCL;和表达ALK的DLBCL。相反，PBL与多中心Castleman病，DLBCL与分泌分化，脓胸相关淋巴瘤，非典型伯基特淋巴瘤与浆细胞样分化的浆细胞分化的形态学外观，但保持成熟的B细胞（CD 20阳性）表型。这些肿瘤以及继发于多发性骨髓瘤或浆细胞瘤的髓外浆细胞瘤也包括在鉴别诊断中。在这篇综述中，我们讨论了最近描述的临床病理学的见解，病例观察，最近报道的分子参与终末B细胞或浆细胞分化及其在疾病发病机制中的可能作用。
Recent evidence suggests that diffuse large B-cell lymphoma (DLBCL) with plasmablastic differentiation represents a clinically heterogeneous spectrum with different clinicopathologic characteristics representing distinct entities. Subtypes of DLBCL with plasmablastic features and terminal B-cell differentiation include plasmablastic lymphoma (PBL) of oral mucosa type; PBL with plasmacytic differentiation; primary effusion lymphoma (PEL); KSHV-positive solid lymphoma/extracavitary PEL/HHV-8 associated DLBCL; and DLBCL expressing ALK. In contrast, PBL associated with multicentric Castleman disease, DLBCL with secretory differentiation, pyothorax-associated lymphoma, and atypical Burkitt lymphoma with plasmacytoid differentiation have morphologic appearances of plasma cell differentiation but maintain a mature B-cell (CD20 positive) phenotype. These tumors as well as extramedullary plasmablastic tumors secondary to multiple myeloma or plasmacytomas are included in the differential diagnosis. In this review, we discuss recently described clinicopathologic insights, case observations, and recently reported molecules involved in terminal B-cell or plasma cell differentiation and their possible roles in disease pathogenesis.